XSHE
002923
Market cap575mUSD
Oct 09, Last price
12.25CNY
1D
6.52%
1Q
14.81%
IPO
48.96%
Name
Zhuhai Rundu Pharmaceutical Co Ltd
Chart & performance
P/E
—
P/S
3.49
EPS
—
Div yield, %
1.30%
Shrs. gr., 5y
-0.20%
Rev. gr., 5y
-0.23%
Revenues
1.18b
-0.51%
Net income
-63m
L
CFO
104m
-50.56%
Dividend
May 30, 20250.15 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zhuhai Rundu Pharmaceutical Co., Ltd., a pharmaceutical firm established in 1997 and based in Zhuhai, China, is engaged in the research, production, and worldwide distribution of pharmaceutical components. The company's diverse portfolio of medicinal ingredients targets key therapeutic areas such as cardiovascular health, gastrointestinal conditions, central nervous system (CNS) disorders, and anesthesia. Its offerings include Active Pharmaceutical Ingredients (APIs), intermediate compounds, finished dosage forms (FDFs), and pellets, which are supplied in common formats like capsules, tablets, and injectable solutions.
Key people
Jie Liu
General Manager, Director · since 2020
Qiang Cai
Deputy General Manager · since 2021
Wei Chen
Deputy General Manager · since 2022
Shenhua Shi
Finance Director, Deputy General Manager · since 2023
Chunyan You
Deputy General Manager, Director · since 2020
Jun Su
Secretary of the Board · since 2022
Liaoran '
Director · since 2023
Xinmin Chen
Chairman of the Board · since 2018
Zhengxi Hu
Independent Director · since 2025
Bo Wang
Independent Director · since 2023
Jianmu Ye
Independent Director · since 2023
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2019‑00 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||||
Revenues | |||||||||||||
Cost of revenue | |||||||||||||
Unusual Expense (Income) | |||||||||||||
NOPBT | |||||||||||||
NOPBT Margin | |||||||||||||
Operating Taxes | |||||||||||||
Tax Rate | |||||||||||||
NOPAT | |||||||||||||
Net income | |||||||||||||
Dividends | |||||||||||||
Dividend yield | |||||||||||||
Proceeds from repurchase of equity | |||||||||||||
BB yield | |||||||||||||
| Debt | |||||||||||||
Debt current | |||||||||||||
Long-term debt | |||||||||||||
Deferred revenue | |||||||||||||
Other long-term liabilities | |||||||||||||
Net debt | |||||||||||||
| Cash flow | |||||||||||||
Cash from operating activities | |||||||||||||
CAPEX | |||||||||||||
Cash from investing activities | |||||||||||||
Cash from financing activities | |||||||||||||
FCF | |||||||||||||
| Balance | |||||||||||||
Cash | |||||||||||||
Long term investments | |||||||||||||
Excess cash | |||||||||||||
Stockholders' equity | |||||||||||||
Invested Capital | |||||||||||||
ROIC | |||||||||||||
ROCE | |||||||||||||
| EV | |||||||||||||
Common stock shares outstanding | |||||||||||||
Price | |||||||||||||
Market cap | |||||||||||||
EV | |||||||||||||
EBITDA | |||||||||||||
EV/EBITDA | |||||||||||||
Interest | |||||||||||||
Interest/NOPBT | |||||||||||||